Royal Bank Of Canada Supernus Pharmaceuticals, Inc. Transaction History
Royal Bank Of Canada
- $479 Billion
- Q4 2024
A detailed history of Royal Bank Of Canada transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 6,940 shares of SUPN stock, worth $223,121. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,940
Previous 5,924
17.15%
Holding current value
$223,121
Previous $184,000
35.87%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$334 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$198 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$155 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$92.5 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$84.5 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.72B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...